Albuterol inhaler for kids
Pro Research Analysisby 
Searched over 200M research papers
Albuterol Inhaler for Kids: Efficacy, Safety, and Delivery Methods
Introduction to Albuterol Inhalers for Pediatric Asthma
Albuterol inhalers are commonly used to manage asthma symptoms in children. These inhalers deliver a bronchodilator that helps open up the airways, making it easier for children to breathe. This article synthesizes recent research on the efficacy, safety, and different delivery methods of albuterol inhalers for pediatric patients.
Metered-Dose Inhalers (MDIs) vs. Nebulizers
Efficacy and Safety Comparison
Recent studies have compared the efficacy and safety of albuterol delivered via metered-dose inhalers with spacers (MDI+S) versus nebulizers (NEB) in children experiencing asthma exacerbations. The findings indicate no significant differences in hospital admission rates between the two methods. However, albuterol delivered through MDI+S showed a significant reduction in the pulmonary index score (PIS) and a smaller increase in heart rate compared to NEB, suggesting better overall outcomes with MDI+S1.
Clinical Implications
The use of MDI+S is increasingly recognized as an effective alternative to nebulization for treating pediatric asthma exacerbations. This method not only provides similar clinical benefits but also offers advantages in terms of ease of use and reduced side effects1.
Albuterol Multidose Dry Powder Inhaler (MDPI)
Efficacy in Pulmonary Function
Albuterol MDPI, a novel inhalation-driven device, has been evaluated for its efficacy in improving pulmonary function in children with asthma. Studies show that albuterol MDPI significantly improves forced expiratory volume in 1 second (FEV1) compared to placebo. The improvements were evident within 5 minutes of dosing and lasted for several hours, with the maximal effect noted 1-2 hours post-dose2 3 5.
Safety Profile
The safety profile of albuterol MDPI is consistent with that of albuterol hydrofluoroalkane (HFA) inhalers. No new safety concerns were noted, and the device was generally well tolerated in pediatric patients2 3 5.
Pharmacokinetics and Pharmacodynamics
Comparative Analysis
A study comparing the pharmacokinetics (PK) and pharmacodynamics (PD) of albuterol MDPI and albuterol HFA in children found that both delivery methods had comparable PK and PD profiles. The maximum observed concentration (Cmax) was larger for albuterol MDPI, but overall, both treatments were well tolerated with no significant adverse events reported4.
Albuterol for Infants
Safety and Efficacy in Infants
In infants with acute obstructive airway disease, albuterol delivered via MDI with a spacer and face mask has been shown to be effective and safe. The treatment significantly reduced the severity of wheezing and retractions without causing significant safety issues6 9.
Conclusion
Albuterol inhalers, whether delivered via MDI+S, MDPI, or nebulizers, are effective in managing asthma symptoms in children. MDIs with spacers and MDPI devices offer significant advantages in terms of ease of use and reduced side effects. These findings support the use of these devices as viable alternatives to traditional nebulization, providing effective and safe asthma management for pediatric patients.
Sources and full results
Most relevant research papers on this topic
Metered-dose inhalers vs. nebulization for the delivery of albuterol for acute exacerbations of wheezing or asthma in children: a systematic review with meta-analysis.
Metered-dose inhalers with a spacer (MDI+S) significantly reduce pulmonary index score and heart rate increase in pediatric asthma patients compared to nebulization.
Meta-Analysis
Rigorous JournalDose-Ranging Efficacy and Safety Study of Albuterol Multidose Dry Powder Inhaler (MDPI) vs Albuterol Hydrofluoroalkane (HFA) and Placebo MDPI in Children With Asthma
Albuterol MDPI significantly improves pulmonary function in children with asthma, with similar effects to albuterol HFA, and its safety profile is consistent with that of albuterol HFA.
RCTRigorous JournalEfficacy and Safety of Albuterol Multidose Dry Powder Inhaler (MDPI) Versus Placebo in Children With Asthma
Albuterol MDPI significantly improves pulmonary function in pediatric asthma patients compared to placebo, with clinical effects evident within 5 minutes and maintained for over 2 hours.
RCTRigorous JournalPharmacokinetics and pharmacodynamics of albuterol multidose dry powder inhaler and albuterol hydrofluoroalkane in children with asthma.
Albuterol MDPI and HFA have comparable pharmacokinetics and pharmacodynamics in children with asthma after a single 180-g dose.
RCTAlbuterol multidose dry powder inhaler efficacy and safety versus placebo in children with asthma.
Albuterol MDPI significantly improves pulmonary function in children with persistent asthma compared to placebo MDPI, with benefits evident within 5 minutes and maintained for over 2 hours.
RCTRepeat Dosing of Albuterol via Metered-Dose Inhaler in Infants With Acute Obstructive Airway Disease: A Randomized Controlled Safety Trial
Repeated dosing of albuterol HFA 180 or 360 mg via metered-dose inhaler in infants with acute obstructive airway disease showed no significant safety issues and improved symptoms by at least 48%.
RCTAlbuterol multidose dry powder inhaler and albuterol hydrofluoroalkane versus placebo in children with persistent asthma.
Albuterol MDPI 90 and 180 g and HFA 180 g both significantly improved FEV1 levels in children with persistent asthma, while HFA 90 g was slightly less effective.
RCTProtective effect of albuterol delivered via a spacer device (Babyhaler®) against methacholine induced bronchoconstriction in young wheezy children
Albuterol delivered through a Babyhaler® with a face mask effectively reduces bronchial hyperreactivity in young wheezy children, providing protection against methacholine-induced bronchoconstriction.
RCTAlbuterol delivered via metered-dose inhaler with spacer for outpatient treatment of young children with wheezing.
Albuterol delivered via metered-dose inhaler with spacer reduces the severity of wheezing and retractions in infants aged 1 to 18 months.
RCTComparison of albuterol delivered by a metered dose inhaler with spacer versus a nebulizer in children with mild acute asthma.
In children with mild acute asthma, 2 puffs of albuterol delivered by an MDI with spacer is as effective as higher doses delivered by an MDI or nebulizer, but may cause greater heart rate changes.
RCT
Highly Cited